Business UpdateJun 3, 2026, 07:31 AM
Biogen to present 14 nephrology data abstracts at ERA & ATC congresses
AI Summary
Biogen announced that 14 abstracts highlighting data from its nephrology portfolio, including EMPAVELI (pegcetacoplan) and investigational felzartamab, have been accepted for presentation at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC). The presentations will showcase sustained efficacy and safety of EMPAVELI in C3G/IC-MPGN from the VALIANT/VALE studies and additional analyses of felzartamab in antibody-mediated rejection (AMR). This highlights the momentum of Biogen's broadened nephrology portfolio.
Key Highlights
- Biogen to present 14 abstracts on its nephrology portfolio at ERA and ATC congresses.
- Presentations include data for EMPAVELI (pegcetacoplan) and investigational felzartamab.
- ERA Congress (June 3-6) will feature new post-hoc analyses from EMPAVELI's Phase 3 VALIANT and VALE studies.
- EMPAVELI data will show sustained efficacy and safety over one year in C3G or primary IC-MPGN patients.
- ATC Congress (June 20-24) will include analyses of Phase 2 felzartamab trial in antibody-mediated rejection (AMR).
- Felzartamab is an investigational anti-CD38 monoclonal antibody for immune-mediated diseases.
- EMPAVELI is approved in the U.S. for C3G/IC-MPGN and PNH.
Price Impact
More from BIIB